Providing clarity and control to women considering abortion.
Microbiotix is a privately held, product-focused biopharmaceutical company engaged in the research and development of novel small molecule, anti-infective drugs that address commercially significant medical markets. The company has four novel compound series in research and development. Microbiotix developed MBX 500, the first antibiotic that targets the deoxyribonucleic acid polymerase of gram-positive bacteria, including drug resistant strains. The company has an active research program to discover a broad-spectrum antibiotic that targets DNA replication of drug-resistant gram-positive and gram-negative bacteria. In addition to MBX 500, Microbiotix's most advanced antiviral compounds are for the treatment of respiratory syncytial virus (MBX 300) and cytomegalovirus (MBX400) which are in pre-clinical development. It also has an active biodefense program, focused on novel therapeutics for Bacillus Anthraocis and Burkholderia pseudomalli. Based in Worcester, Mass., Microbiotix is involved in the discovery of inhibitors of bacterial biofilm formation and antibiotic resistance.
As a member of the construction industry, you are aware of the growing importance of field quality control services offered by testing laboratories. The need for a quality engineering & testing laboratory has become apparent, and Yankee Engineering & Testing has been formed to meet this need. Yankee Engineering & Testing, Inc. uses the most modern equipment available to test materials and provide concise, understandable results in a timely manner. Our equipment is calibrated and reviewed annually. Personalized service in the field, as well as in the laboratory, is a must for every project. Nuclear Density Testing Topsoil/Loam Analyses Gradation (sieve) Analyses concrete Field Slump/Air/Rebar Plant Monitoring Services Compression Testing of Cylinders Concrete Mix Reviews Coring Services Swiss Hammer Windsor Probe Testing Rebar Location Services Fireproofing Review of Field Operations Adhesion/Cohesion ("Pull Tests") Moisture/Density Test Cuts Masonry Review of Fie
The Quest Diagnostics difference. Bringing together quality, speed, and technology to power advanced, affordable diagnostics for all. No trade-offs required.
Quest Diagnostics empowers people to take action to improve health outcomes. The company was founded in April 1967 as Metropolitan Pathology Laboratory, Inc. Corning Glass Works acquired the company in 1982 and later spun it off as a publicly traded company under the name Quest Diagnostics, at the beginning of 1997. Quest has developed countless innovative diagnostic information services, with several firsts for clinical laboratory tests in areas such as women's health, genetics, infectious diseases and cancer. Today, Quest provides thousands of laboratory services, from genetic tests to predict cancer risk to biological tests for diabetes and heart disease, to empower people to take action to improve health outcomes. One in three American adults and one in two physicians and hospitals use the company's services each year, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
Quest Diagnostics empowers people to take action to improve health outcomes. The company was founded in April 1967 as Metropolitan Pathology Laboratory, Inc. Corning Glass Works acquired the company in 1982 and later spun it off as a publicly traded company under the name Quest Diagnostics, at the beginning of 1997. Quest has developed countless innovative diagnostic information services, with several firsts for clinical laboratory tests in areas such as women's health, genetics, infectious diseases and cancer. Today, Quest provides thousands of laboratory services, from genetic tests to predict cancer risk to biological tests for diabetes and heart disease, to empower people to take action to improve health outcomes. One in three American adults and one in two physicians and hospitals use the company's services each year, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
